Threshold Pharmaceuticals, Inc. (THLD): A Biotech That Investors Need To Know About

Page 1 of 2

Biotech stocks can provide astronomical returns but also depressing losses. Before investing in these volatile stocks, investors need to understand the full picture, including fundamentals, technical, and upcoming catalysts. Below are 2 biotechs that appear to be well on their way to greatness.

Threshold Pharmaceuticals, Inc. (NASDAQ:THLD)

Threshold Pharmaceuticals, Inc. (NASDAQ:THLD)

Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) is an early stage biotechnology company engaged in the discovery, development, and commercialization of cancer therapeutics based on a novel and powerful approach of targeting tumor hypoxia. There is a lot to like about Threshold Pharmaceuticals, Inc. (NASDAQ:THLD), including its recent trading action, fundamentals, partnerships, and upcoming business catalysts. The 2 year chart below shows the large trading move that the stock has seen.

The share price saw a large jump in early 2012 because of a flurry of positive press releases. Threshold announced a partnership with Merck KGaA (known as the “German Merck”.) Merck KGaA is very well known in Germany and is one of the largest biotechnology companies in Europe. The deal was extremely favorable for Threshold. Under the terms of the deal, Threshold received a $25 million upfront payment. Additionally, the company received a $20 million milestone payment based on positive results from its randomized Phase II clinical trial for pancreatic cancer. In total, the agreement gives Threshold the opportunity to earn up to $525 million in total milestone payments. The real bright spot of the deal is that Merck KGaA agreed to pay 70% of the worldwide development costs for TH-302. This means that investors will have to worry less about dilution than is normally typical for biotech companies of this size.

As mentioned above, this agreement is for Threshold Pharmaceuticals, Inc. (NASDAQ:THLD)’s therapy candidate called TH-302. TH-302 is being tested in multiple studies for the treatment of pancreatic cancer, soft tissue sarcoma, and other solid tumors. The two main trials for Threshold are TH-CR 406 and MAESTRO. TH-CR 406 is a Phase III clinical trial of TH-302 in combination with doxorubicin to treat patients with soft tissue sarcoma. MAESTRO is a Phase III clinical trial of TH-302 in combination with gemcitabine to treat patients with pancreatic cancer. The company is expected to release interim results of these trials in the fall this year with complete results expected in late 2014.

Fundamentally, Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) also appears to be making great strides. For biotechs, cash is king. Threshold ended 2012 with $11 million in cash & cash equivalents and $59.8 million in short term investments for a total of $70.8 million. This was an increase of approximately $50 million from 2011 cash levels. Threshold also improved on the income statement by generating $5.9 million in revenue compared to just $62,000 for 2011.

Risks

Despite all of the above, it’s important for investors realize the potential downfalls to investing in Threshold Pharmaceuticals, Inc. (NASDAQ:THLD). First, the volatility for Threshold has been intense over the past 2 years. The share price traded as low $1.20 and as high as $9.28. It now trades at $5.48 and appears to have settled down but that will most likely change later this year once trial results are released. Second, the competition for pancreatic cancer therapies is intense. Celgene Corporation (NASDAQ:CELG) is heavily involved in this area with its potential therapy called Abraxane. In fact, just recently, the US Food and Drug Administration granted priority review for Abraxane. Celgene is seeking approval of Abraxane in combination with a product called Gemzar.. Should Abraxane receive approval, Celgene stands to gain a foothold on the market and potentially put Threshold in a catch up position. Additionally, Celgene Corporation (NASDAQ:CELG) could potentially be a tough opponent for Threshold based on its fundamentals. Analysts are expecting Celgene to show sales growth of 11.7% in 2013 and 14.5% in 2014. On top of that, Celgene was able to grow its year over year revenue by 13.5% from $4.84 billion to $5.5 billion. Celgene Corporation (NASDAQ:CELG) is not a company to be taken lightly and Threshold investors should understand this.

Page 1 of 2

Biotech Insider Alert - $6 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The Greatest Directors in the World

Largest Animals in the World

World’s Most Expensive Desserts

Best Selling Comic Books of All Time

A-list Actors who Sabotaged Their Career

Rappers With a College Degree

The Best Jazz Albums of all Time

The Most Influential Jazz Musicians

The World’s Most Famous Photographers

The Best Oscar-Winning Songs

Most Influential Choreographers Ever

Most Expensive Department Stores in the World

The Most Expensive Stolen Paintings in the World

The World’s Most Expensive Teas

Top Oscar Record Holders

The Most Expensive Flowers in the World

Countries With a Booming Film Industry

Most Expensive Cupcakes in the World

Uncommon European Escapes

The Most Stolen Artists in History

Best Travel Destinations in Australia

World’s Most Expensive Musical Instruments

World’s Most Famous Animals

Most Expensive Cakes in the World

Most Expensive Kosher Champagne in the World

Most Expensive Kosher Wine in the World

The Most Surprisingly Dark Fairy Tales

Most Popular Travel Destinations in Asia

The 10 Most Expensive Dresses Ever Worn to the Oscars

World’s Most Visited Art Museums

Best Countries for Photographers to Work in

Best Paid Jobs in the Film Industry

The Most Renowned Recovered Paintings Ever

Child Stars That Turned out Just Fine

Books That Were Banned in the Past Century

World’s Richest Dancers

Best Remedies against Bad Breath

Foods That Improve Your Skin Texture

Best-Selling Children’s Books of all Time

Foods That Boost Your Libido

Best-Selling Books of all Time

The Most Expensive Academy Awards Jewelry in History

Most Expensive Japanese Restaurant In New York City

The Best B-Boy Movies

Most Awesome Hip Hop Documentaries

Foods That Stain Your Teeth

Richest Doctors in the World

The Best Movie Sountracks Ever

The Highest Grossing Musicals on Broadway

The Most Successful Reality TV Stars

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!